BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250227T190000
DTEND;TZID=Africa/Nairobi:20250227T203000
DTSTAMP:20260528T172518
CREATED:20250611T193814Z
LAST-MODIFIED:20250622T142307Z
UID:38891-1740682800-1740688200@kesho-kenya.org
SUMMARY:AML: A Local Perspective
DESCRIPTION:Moderator: Prof Abinya \nSpeakers & Topics: \n\nDr Anne Mwirigi: Local Experience at a Tertiary Hospital\nDr Rohini Radia: The Role of Cytogenetics & Molecular Markers\nDr Peter Oyiro: Genomic Classification & Medical Oncology Pathways\nDr Beatrice Jepngetich: Panelist Discussion\nDr Mercy Gatua: Panelist Discussion\n\n Summary \nAML is genetically heterogeneous\, with most patients having multiple driver mutations.\n– WHO 2022 classification emphasizes genetic abnormalities over morphology or blast count.\n– Defining cytogenetic lesions like inv(16) or t(8;21) now suffice for diagnosis even with <20% blasts. \nDiagnostic Work-Up \n– FBC and peripheral blood smear\n– Bone marrow aspirate: morphology\, flow cytometry\, LAIP for MRD\n– Cytogenetics: Karyotyping and FISH\n– Next-Generation Sequencing (NGS): TP53\, NPM1\, etc.\n– Bone marrow trephine with immunocytochemistry. \nClinical Implications \n– Risk stratification through cytogenetics + molecular testing informs prognosis and treatment plan.\n– Favorable-risk patients may receive chemotherapy; adverse-risk patients considered for early allogeneic transplant.\n– MRD monitoring increasingly guides transplant decisions. \nTakeaways \n– AML is curable in a subset with intensive chemo + risk-adapted approach.\n– Precision oncology depends on accessible molecular diagnostics.\n– LMICs face challenges integrating NGS-based stratification.\n– Hypomethylating agents + Venetoclax offer promise in select patient groups.
URL:https://kesho-kenya.org/event/aml-a-local-perspective/
LOCATION:Aga Khan University\, Nairobi
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/A-Local-Perspective-e1749671173338.jpg
END:VEVENT
END:VCALENDAR